Table 2.
Univariable and multivariable Cox proportional hazard regression models for OS in PCaBM with GS 8–10.
| Univariable |
Multivariable |
|||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (>74 yrs)a) | 1.96 | 1.15–3.31 | 0.01 | 1.54 | 0.86–2.76 | 0.15 |
| BMI (>22)a) | 0.67 | 0.40–1.13 | 0.13 | — | — | — |
| PSA (> 458 ng/mL)a) | 0.93 | 0.56–1.55 | 0.78 | — | — | — |
| Total prostate volume (> 35 mL)a) | 0.84 | 0.48–1.45 | 0.53 | — | — | — |
| PSA density (> 10)a) | 0.78 | 0.45–1.35 | 0.37 | — | — | — |
| Positive/ total biopsy core (≥ 0.9)a) | 1.58 | 0.93–2.7 | 0.09 | — | — | — |
| WBC (> 860/μL)b) | 1.07 | 0.57–1.99 | 0.83 | — | — | — |
| Hb (> 13 g/dL)b) | 0.57 | 0.33–0.97 | 0.04 | 1.01 | 0.34–3.01 | 0.55 |
| Plt (> 35 × 104/μL)b) | 1.07 | 0.38–2.97 | 0.89 | — | — | — |
| NLR (> 2.7)a) | 1.32 | 0.78–2.23 | 0.3 | — | — | — |
| ALP (> 320 U/L)b) | 1.49 | 0.86–2.59 | 0.15 | — | — | — |
| Alb (> 4 g/dL)b) | 0.49 | 0.29–0.83 | < 0.01 | 0.55 | 0.31–0.99 | 0.04 |
| ≥ T3b | 1.59 | 0.84–3 | 0.16 | — | — | — |
| Lymph node metastasis | 1.41 | 0.77–2.57 | 0.27 | — | — | — |
| Visceral metastasis | 0.7 | 0.3–1.63 | 0.41 | — | — | — |
| High volume | 1.67 | 0.93–3.02 | 0.08 | — | — | — |
| EOD ≥ 3 | 1.71 | 0.99–2.72 | 0.05 | — | — | — |
| GS 9–10 (vs. GS 8) | 1.9 | 1.01–3.59 | 0.04 | 1.8 | 1.01–3.08 | 0.04 |
| GS 5+4, 10 (vs. GS 8, 4+5) | 1.24 | 0.73–2.1 | 0.42 | — | — | — |
| GS 10 (vs. GS 8–9) | 0.99 | 0.42–2.32 | 0.98 | — | — | — |
Alb, albumin; ALP, alkaline phosphatase; CI, confidence interval; EOD, extent of disease; GS, Gleason Score; Hb, hemoglobin; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PCaBM, prostate cancer with bone metastasis; Plt, platelets; PSA, prostate-specific antigen; WBC, white blood cell.
a)
Median.
b)
Normal or abnormal value.